Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Chronic Kidney Disease of Predominantly Glomerular Origin: A Two-Year Comparative Cohort Study with Historical Controls
Background/Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are established in the treatment of chronic kidney disease (CKD), but evidence in CKD caused by glomerular disease is limited, and patients on intensified immunosuppression have been excluded from the randomised trials. We examined the effect of d...